Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology | Family Medicine
Disease Category: Depression (Major/Severe)
Location: United States, IL
A phase 3, randomized, double blind, parallel group, placebo-controlled, fixed dose study comparing the efficacy and safety of 2 doses (10 and 15mg) of Lu AA21004 in acute treatment of adults with major depressive disorder.
The purpose of this study is to evaluate if 10 and 15mg of Lu AA21004 (the study drug) once a day compared with placebo will improve major depressive symptoms after eight weeks of treatment in patients with major depressive disorder.
Please contact Alexian Brothers for more information on participation.
Alexian Brothers Hospital Network
1786 Moon Lake Boulevard, Suite 200
Hoffman Estates, IL 60169
If you would like to learn more about participating in this study, please send an email message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these